Trinity Capital Invests $45 Million in Rapid Micro Biosystems

Trinity Capital Inc. has committed $45 million in growth capital to Rapid Micro Biosystems, announced in a press release. Rapid Micro Biosystems specializes in automating microbial quality control processes, which are crucial for the efficient manufacturing and safe release of healthcare products.

The investment will aid in scaling Rapid Micro's operations, including the global expansion of its Growth Direct platform. This platform automates microbial quality control testing, providing faster and more accurate results, thereby enhancing operational efficiency and data integrity. The funding will also support efforts to reduce product costs and improve manufacturing efficiencies.

Robert Spignesi, President and CEO of Rapid Micro Biosystems, expressed satisfaction with the partnership, highlighting the shared vision of automating manual testing methods in biopharma manufacturing. This financial boost is expected to strengthen Rapid Micro's market position and support its long-term growth objectives.